Exagen logo_440x386 (1).jpg
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
January 09, 2022 12:00 ET | Exagen Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual...
Exagen logo_440x386 (1).jpg
Exagen Inc. Reports Third Quarter 2021 Results
November 10, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021....
Exagen logo_440x386 (1).jpg
Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
October 27, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
October 27, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered...
Exagen logo_440x386 (1).jpg
Exagen Inc. Announces $27.2 Million Debt Refinancing
October 25, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security...
Exagen_Full_CMYK_Print.jpg
Exagen to Present at Cowen and Company 40th Annual Healthcare Conference
February 18, 2020 08:25 ET | Exagen, Inc.
SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Exagen_Full_CMYK_Print.jpg
Exagen Announces Addition to Russell 3000® and 2000® Indexes
December 16, 2019 08:25 ET | Exagen, Inc.
SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Exagen Diagnostics t
Exagen Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
October 30, 2018 10:30 ET | Exagen Diagnostics, Inc.
Albuquerque, NM and San Diego, CA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life sciences, today announced that President and Chief Executive Officer, Ron Rocca,...
Exagen Diagnostics A
Exagen Diagnostics Announces Evidence Development Agreement with a Large Mid-Atlantic Health Insurer for the AVISE® Lupus Test
August 20, 2018 11:20 ET | Exagen Diagnostics, Inc.
Albuquerque and San Diego, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics Announces Evidence Development Agreement with a Large Mid-Atlantic Health Insurer for the AVISE® Lupus Test, see full...